A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
BUSINESS
Local Anesthetic Runs Short in Japan Due to Curbed Supply of Sandoz’ Anapeine
The restricted shipments of the long-acting local anesthetic Anapeine (ropivacaine) is starting to take a toll on medical operations in Japan. According to Sandoz, which markets the drug, a deviation was identified when the company switched its contract manufacturer, resulting…
To read the full story
Related Article
- Terumo Puts Brake on Supply of Anapeine Generics
November 21, 2024
- Terumo Rolls Out Anapeine Generics after Expedited Listing
November 13, 2024
- Anapeine Generics Get Expedited Listing amid Supply Crunch
November 12, 2024
- Sandoz Gives Update on Anapeine Supply after Manufacturing Change
October 30, 2024
- Local Anesthetic Supply Won’t Recover Soon Despite New Site Approval: Specialist
October 28, 2024
- Sandoz Japan Gets OK to Add New Manufacturing Site for Anapeine
October 15, 2024
- Supply of Anapeine Generic to Start by Year-End: Minister
October 9, 2024
- Anapeine Restriction Forcing Sandoz to Curb Supply of More Local Anesthetics
August 7, 2024
BUSINESS
- ASKA/Veneno Tie Up for Discovery of Ion Channel Therapies
January 15, 2025
- Kyorin, Biodol Ink Option Deal for Novel Pain Drug
January 15, 2025
- Nippon Shinyaku Grabs Rights to Regenxbio’s MPS Gene Therapies
January 15, 2025
- Chugai to Transfer Tarceva to Cheplapharm in April
January 15, 2025
- Daiichi Buys IP Rights to Glycotope’s TA-MUC1 Antibody
January 15, 2025
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…